Loading...
Market
What will be the improvement in PANSS score for NBI-1117568 in subsequent trials by end of 2025?
2
Resolution / Starting Odds
Improvement of 7.5-10 points • 25%
Improvement of 10-12.5 points • 25%
Improvement of 12.5-15 points • 25%
Improvement of more than 15 points • 25%
Clinical trial results published by Neurocrine Biosciences or medical journals
Story
Neurocrine's Schizophrenia Drug Shows 7.5 Point Improvement in Phase 2 Trial; Shares Drop 15.6%
Aug 28, 2024, 11:33 AM
Neurocrine Biosciences has announced positive results from a mid-stage Phase 2 study of its experimental drug NBI-1117568 for treating schizophrenia in adults. The study achieved its main goal, showing a 7.5 point improvement on the PANSS score with a 20 mg daily dose, which was statistically significant. However, no improvement was observed with higher doses. Despite the positive outcome, the company's shares have dropped by 15.6% in pre-market trading as investors reacted to the mixed results of the trial.
View original story
Similar markets
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Primary endpoint met • 25%
Primary endpoint not met • 25%
Trial halted due to safety concerns • 25%
Other • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Significant advancements in PKU treatment • 25%
Significant advancements in autoimmune disease research • 25%
No significant advancements • 25%
Other • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%